The Breast Cancer Debate of the Year 2025 brings together leading experts for an evidence-based discussion of key clinical dilemmas in contemporary breast cancer management. Through structured debates and real-life case presentations, this course focuses on translating emerging data into daily clinical practice.

Chaired by Evandro de Azambuja and Hans Wildiers, the programme addresses treatment escalation and de-escalation strategies, innovation in diagnostics, and optimal sequencing of systemic therapies.

Key topics include the use of adjuvant CDK4/6 inhibitors in node-positive luminal disease, omission of radiotherapy in older patients with low-risk breast cancer, the clinical readiness of liquid biopsy in early and metastatic settings, and a critical review of second-line therapy in HR+/HER2- metastatic breast cancer.

This course is designed for healthcare professionals involved in the multidisciplinary care of patients with breast cancer who seek a concise, practice-oriented update on current controversies and evolving standards of care.